甲磺酸伊马替尼治疗胃肠道间质瘤的研究进展

摘要

Gastrointestinal stromal tumor(GIST)is the most common mesenchymal malignancy of the gastrointestinal tract and abdominal cavity.It is unresponsive to standard chemotherapy and to radiotherapy.The main treatment is surgery for limitations of GIST patients,but the postoperative recurrence rate of GIST patients is higher,for preopera-tive,postoperative adjuvant,recurrence,metastasis and not surgical resection of the GIST patients.Tyrosine kinase in-hibitor imatinib mesylate has good effect.This article will review the research progress of imatinib mesylate on gastro-intestinal stromal tumor.%胃肠道间质瘤（GIST）是胃肠道及腹腔最常见的间叶源性肿瘤，对常规的放疗、化疗均不敏感。外科手术是局限性GIST患者的主要治疗方式，但术后复发率较高。对于术前、术后辅助、复发、转移及不能手术切除的患者，酪氨酸激酶抑制剂甲磺酸伊马替尼对其有较好的治疗效果。本文对甲磺酸伊马替尼治疗胃肠道间质瘤的研究进展作一综述。